Ultivue and OracleBio Partner to Help Advance Personalized Tumor Characterization and Clinical Oncology Research Using Multiple Immunofluorescence
24 July 2020
Ultivue , Inc. announced a collaboration agreement with OracleBio that will help gain greater insight and advance personalized tumor characterization in translational and clinical cancer research and development. of drugs by multiple immunofluorescence staining and image analysis.
The agreement connects OracleBio's histopathology image analysis expertise and Ultivue's tissue staining capabilities with the goal of providing pharmaceutical companies with a comprehensive workflow that enables valuable biomarker insights to be obtained on-site.
The statement in the original language is the official and authorized version of it. The translation is only a means of help and should be compared with the text in the original language, which is the only version of the text that will have legal validity.
Contacts
Lorcan Sherry
OracleBio
lorcan.sherry@oraclebio.com
Christopher Hynes
Ultivue
christopher.hynes@ultivue.com
Source: businesswire.com